Every clinician who tested Niramai's screening tool has purchased it
Dr. Geetha Manjunath · Dr. Geetha Manjunath on building Niramai, the most affordable product for breast cancer detection · Feb 18, 2021 · at 41:11
Dr. Geetha Manjunath, founder and CEO of Niramai, explains how conducting blind clinical trials for skeptical doctors consistently converts them into paying customers.
0:00 / 0:03exact quote · 3.9s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Anyone who has tested actually sort of gone ahead and bought the solution.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dr. Geetha Manjunath
Mammography fails for women under 45 due to dense breast tissue
“It does not work on women under 45 years of age because what we call as dense press, you know, The kind of fibroglandial tissue that many of the men who are like about what if I also have this and also younger women definitely have this. So, so the whole breas…”
Niramai's thermal tech works on all ages and men regardless of density
“It does work on women of all age groups because it does not depend on density. It just depends on body temperature and which all of us have similar. It does work on male as well, not just for women.”
Niramai's thermal tech can be applied to detect other cancers
“It's a technology that we have developed and can be used for several other types of cancers because all other types of cancers or many, many Of those also depict a similar thermal signature that we can find too. So not just for cancer as well, this can be used…”
Mammography is the only test proven to increase survival rates
“And actually it's one of in fact, it's the only test which is proven to increase you know, increase the survival rates of women in terms of, you know, really large clinical trials and so on.”